This trial is active, not recruiting.

Conditions depression, dysthymia
Treatment escitalopram and sertraline
Phase phase 4
Sponsor Oregon Health and Science University
Collaborator Forest Laboratories
Start date September 2005
End date October 2006
Trial size 40 participants
Trial identifier NCT00234312, 04-2801-A 02


The purpose of the study is to evaluate the efficacy and safety of flexible doses of escitalopram (Lexapro) compared to sertraline (Zoloft) for treatment of Dysthymic Disorder.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification safety/efficacy study
Intervention model single group assignment
Masking single blind
Primary purpose treatment

Primary Outcomes

score on first 17 items of HAM-D Rating Scale 24 item, each visit
time frame:

Secondary Outcomes

scores on HAM-D 21, HAM-D 24, and Beck Depression Inventory (pt. rated)
time frame:

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - Primary diagnosis of Dysthymic Disorder or Major Depressive Disorder with Antecedent Dysthymia - Women of childbearing potential must have negative pregnancy test at screen and agree to practice acceptable method of birth control - Score of at least 12 on the 24-item Hamilton Depression Scale at study entry - Initial screening labs grossly within normal limits - Signed written informed consent Exclusion Criteria: - Other Axis-I diagnoses such as delirium, dementia, and substance dependence (active in last year) or any substance abuse including alcohol within the past six months - Actively suicidal - CNS neoplasm, demyelinization disease, degenerative neurological disorder, active CNS infection, or any progressive CNS disorder that may confound interpretation of study results - History of seizure disorder, or EEG showing paroxysmal activity or head CT showing gross structural abnormality - Acute systemic medical disorder - Use of any psychotropic medications within 2 weeks prior to screen or 4 weeks prior to screen in the case of fluoxetine - Current use of any herbal medication such as St. John's wort, - Uncontrolled renal, hepatic, endocrine, cardiovascular, pulmonary, immunological, hematological or gastrointestinal disease - Any other abnormal medical screening tests judged by the investigator to be clinically significant - Received any experimental medication within 30 days prior to study entry - Patients presently in or soon to be starting psychotherapy - Prior treatment non-response to an adequate trial of citalopram, escitalopram, or sertraline - History of allergy to citalopram, escitalopram or sertraline

Additional Information

Official title Escitalopram Vs. Sertraline in the Treatment of Dysthymic Disorder and Double Depression
Principal investigator Joshua Boverman, MD
Description Dysthymic Disorder is a common, chronic type of depression that is often seen as a mild condition and is under-treated. Because of its chronic course, it is often complicated by episodes of major depression and may require long-term treatment. This is a twelve week study during which daily doses of escitalopram (10-20 mg) or sertraline (50-200 mg) will be given to outpatients meeting criteria for Dysthymic Disorder or Double Depression. Medications will be assigned 1:1 and clinicians will be blinded to treatment. Efficacy will be based on scores for the Hamilton Depression Rating Scale, patient subjective reporting, and clinician observation. The study will have a total of 8 visits over 12 weeks, with a one-week medication taper period at the end. Subjects will have a physical exam, labs, and vital signs monitored at first visit and vital signs monitored at every subsequent visit. Women of childbearing potential must have a negative urine pregnancy test at screening. All subjects will remain on the lowest medication dose for the first four weeks of the study.
Trial information was received from ClinicalTrials.gov and was last updated in September 2006.
Information provided to ClinicalTrials.gov by Oregon Health and Science University.